InnovivaINVA +0.20%88 Buyback Yield % is 1.37 as of Jul. 12, 2026, which is 42% below its 10-year median of 2.37. GuruFocus rates INVA with a GF Score™ of 88/100 and a GF Value™ of $20.43 (Fairly Valued). The stock has 5 warning signs investors should review. Among 742 Biotechnology companies, Innoviva ranks better than 94.34% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Innoviva's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INVA vs BCAX, ZYME, SRPT: Buyback Yield % Comparison
For the Biotechnology subindustry, Innoviva's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innoviva Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innoviva's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Innoviva's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva (INVA) has a Buyback Yield % of 1.37 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Innoviva and its competitors. This is 42% below median its historical median of 2.37. According to the industry distribution chart, Innoviva ranks #42 out of 742 companies in the Biotechnology industry, placing it in the top 5.7%.
Is Innoviva's Buyback Yield % too high?
Innoviva's current Buyback Yield % of 1.37 is 42% below median its 10-year median of 2.37. Based on the distribution chart, Innoviva ranks #42 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innoviva has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innoviva's Buyback Yield % compare to BCAX and ZYME?
According to the Biotechnology industry distribution chart, Innoviva ranks #42 out of 742 companies for Buyback Yield %. This places Innoviva in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Innoviva and its competitors. Innoviva's current Buyback Yield % is 1.37, which is 42% below median its own 10-year median of 2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoviva stock overvalued right now?
Based on GuruFocus' analysis, Innoviva (INVA) is currently considered Fairly Valued. The stock's GF Value™ is $20.43, compared to a current price of $22.23 — trading 8.8% above its estimated fair value. The current Buyback Yield % is 1.37, which is 42% below median its 10-year median of 2.37. Innoviva's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Innoviva (INVA), the current Buyback Yield % is 1.37 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innoviva (INVA) Overvalued in 2026?
Based on GuruFocus' analysis, Innoviva stock appears to be overvalued.
The current stock price of $22.23 is trading 8.8% above its estimated GF Value™ of $20.43.
GuruFocus considers Innoviva to be Fairly Valued.
Key valuation signals for INVA:
Buyback Yield %: 1.37 (42% below median its 10-year median of 2.37)
GF Value™: $20.43 vs. price of $22.23 (8.8% above fair value)
No single metric tells the full story. See the INVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
88GF Score
Get the complete analysis for INVA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INVA has been successfully added to your 
